Table 1 Summary of some PPI modulators in clinical trials
PPI | Related disease | Drug | Developer | Status | NCT number | Refs. |
|---|---|---|---|---|---|---|
Small molecules | ||||||
MDM2/p53 | Acute myeloid leukemia | Idasanutlin | Roche | Phase III | NCT02545283 | |
MDM2/p53 | Metastatic melanoma | AMG232 | Amgen | Phase I/II | NCT02110355 | |
MDM2/p53 | Solid tumor with p53 wild type status | CGM097 | Novartis | Phase I | NCT01760525 | |
MDM2/p53 | Advanced solid tumor, lymphoma | DS-3032b | Daiichi Sankyo | Phase I | NCT01877382 | |
MDM2/p53 | Neoplasm malignant | SAR405838 | Sanofi | Phase I | NCT01636479 | |
Bcl-2/Bax | Chronic lymphocytic leukemia | ABT-199 | AbbVie | Approved in 2016 | – | |
XIAP/caspase-9 | Relapsed or refractory multiple myeloma | LCL-161 | Novartis | Phase II | NCT01955434 | |
XIAP/caspase-9 | Recurrent head and neck squamous cell carcinoma | TL32711 | National Cancer Institute | Phase I | NCT03803774 | |
XIAP/caspase-9 | Solid tumors, lymphoma | ASTX-660 | Astex | Phase I/II | NCT02503423 | |
XIAP/caspase-9 | Solid cancers | GDC-0917 | Genentech | Phase I | NCT01226277 | |
PD-1/PD-L1 | Prostatic neoplasms | CA-170 | Astellas | Phase II | NCT01288911 | |
Gp120/CCR5 | HIV | Maraviroc | Pfizer | Approved in 2007 | – | |
LFA-1/ICAM-1 | Dry eye | Lifitegrast | Lifelong Vision Foundation | Phase IV | NCT03451396 | |
Β-catenin/CBP | Liver cirrhosis | RPI-724 | Komagome Hospital | Phase I/II | NCT03620474 | |
Bromodomain/histone | Cardiovascular diseases | RVX-208 | Resverlogix | Phase III | NCT02586155 | |
Bromodomain/histone | NUT midline carcinoma | GSK525762 | GSK | Phase I | NCT01587703 | |
Peptides | ||||||
MDM2/p53 | Advanced solid tumors, lymphomas | ALRN-6924 | Aileron | Phase I/II | NCT02264613 | |
Antibodies | ||||||
CD40/CD40L | Kidney transplantation | Bleselumab | Astellas | Phase II | NCT02921789 | |
CD40/CD40L | Multiple myeloma | lucatumumab | Novartis | Phase I | NCT00231166 | |
CD40/CD40L | Relapsed diffuse large B-cell lymphoma | dacetuzumab | Seattle Genetics | Phase II | NCT00435916 | |
CD40/CD40L | Lupus Nephritis | BI655064 | Boehringer Ingelheim | Phase II | NCT03385564 | |
CD40/CD40L | Advanced solid tumors | ABBV-428 | AbbVie | Phase I | NCT02955251 | |
CD40/CD40L | Ulcerative colitis | ABBV-323 | AbbVie | Phase II | NCT03695185 | |
PD-1/PD-L1 | Non-small lung cancer | Keytruda | Merck Sharp & Dohme | Approved in 2014 | – | |
PD-1/PD-L1 | Non-small lung cancer | Opdivo | Bristol Myers Squibb | Approved in 2014 | – | |
PD-1/PD-L1 | Non-small lung cancer | Tecentriq | Roche | Approved in 2016 | – | |
PD-1/PD-L1 | Merkel cell carcinoma | Bavencio | Merck and Pfizer | Approved in 2017 | – | |
PD-1/PD-L1 | Non-small lung cancer | Imfinzi | AstraZeneca | Approved in 2017 | – | |
PD-1/PD-L1 | Unresectable or metastatic melanoma | JS001 | Shanghai Junshi Bioscience | Phase III | NCT03430297 | |
PD-1/PD-L1 | Advanced/metastatic solid malignancies | IBI308 | Innovent Biologics | Phase I/II | NCT03568539 | |
PD-1/PD-L1 | Locally advanced or metastatic urothelial bladder cancer | BGB-A317 | BeiGene | Phase II | NCT04004221 |
